Real Heart
Scandinavian Real Heart AB (Publ) engages in the design and development of an artificial heart. The company develops Realheart TAH to treat advanced stage heart failure. It also develops RealVAD for pulsating left ventricle assist; PulsePump, a pulsating flow for heart and lung machines; and Sternal Prosthesis to fix the sternum after open-chest surgery. The company was founded in 1999 and is bas… Read more
Real Heart (HEART) - Net Assets
Latest net assets as of June 2025: Skr74.35 Million SEK
Based on the latest financial reports, Real Heart (HEART) has net assets worth Skr74.35 Million SEK as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr87.94 Million) and total liabilities (Skr13.59 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr74.35 Million |
| % of Total Assets | 84.54% |
| Annual Growth Rate | 36.11% |
| 5-Year Change | -6.07% |
| 10-Year Change | 1028.55% |
| Growth Volatility | 331.37 |
Real Heart - Net Assets Trend (2010–2024)
This chart illustrates how Real Heart's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Real Heart (2010–2024)
The table below shows the annual net assets of Real Heart from 2010 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Skr67.34 Million | -17.92% |
| 2023-12-31 | Skr82.04 Million | -15.98% |
| 2022-12-31 | Skr97.65 Million | -12.26% |
| 2021-12-31 | Skr111.29 Million | +55.23% |
| 2020-12-31 | Skr71.69 Million | +21.51% |
| 2019-12-31 | Skr59.00 Million | +205.70% |
| 2018-12-31 | Skr19.30 Million | -29.87% |
| 2017-12-31 | Skr27.52 Million | +69.86% |
| 2016-12-31 | Skr16.20 Million | +171.52% |
| 2015-12-31 | Skr5.97 Million | -20.41% |
| 2014-12-31 | Skr7.50 Million | +1285.74% |
| 2013-12-31 | Skr541.04K | -32.25% |
| 2012-12-31 | Skr798.57K | -1.66% |
| 2011-12-31 | Skr812.04K | -9.64% |
| 2010-12-31 | Skr898.64K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Real Heart's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 16960153800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr10.36 Million | 15.39% |
| Other Components | Skr226.66 Million | 336.59% |
| Total Equity | Skr67.34 Million | 100.00% |
Real Heart Competitors by Market Cap
The table below lists competitors of Real Heart ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Wahana Ottomitra Multiartha
JK:WOMF
|
$4.88 Million |
|
3 E Network Technology Group Ltd Class A Ordinary Shares
NASDAQ:MASK
|
$4.88 Million |
|
Subur Tiasa Holdings Bhd
KLSE:6904
|
$4.88 Million |
|
onesano S.A.
WAR:ONO
|
$4.88 Million |
|
Thunderbird Resources Ltd
AU:THB
|
$4.88 Million |
|
MILA RESOUR. PLC LS-01
F:HN0
|
$4.88 Million |
|
Intellipharmaceutics International Inc
OTCQB:IPCIF
|
$4.88 Million |
|
CJ Century Logistics Holdings Bhd
KLSE:7117
|
$4.88 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Real Heart's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 82,037,974 to 67,340,121, a change of -14,697,853 (-17.9%).
- Net loss of 34,350,000 reduced equity.
- New share issuances of 19,585,388 increased equity.
- Other comprehensive income increased equity by 138,814,289.
- Other factors decreased equity by 138,747,530.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-34.35 Million | -51.01% |
| Share Issuances | Skr19.59 Million | +29.08% |
| Other Comprehensive Income | Skr138.81 Million | +206.14% |
| Other Changes | Skr-138.75 Million | -206.04% |
| Total Change | Skr- | -17.92% |
Book Value vs Market Value Analysis
This analysis compares Real Heart's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.41x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 257.78x to 0.41x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2010-12-31 | Skr0.05 | Skr13.50 | x |
| 2011-12-31 | Skr0.05 | Skr13.50 | x |
| 2012-12-31 | Skr0.05 | Skr13.50 | x |
| 2013-12-31 | Skr0.03 | Skr13.50 | x |
| 2014-12-31 | Skr0.44 | Skr13.50 | x |
| 2015-12-31 | Skr0.35 | Skr13.50 | x |
| 2016-12-31 | Skr0.86 | Skr13.50 | x |
| 2017-12-31 | Skr1.20 | Skr13.50 | x |
| 2018-12-31 | Skr0.86 | Skr13.50 | x |
| 2019-12-31 | Skr208.01 | Skr13.50 | x |
| 2020-12-31 | Skr206.17 | Skr13.50 | x |
| 2021-12-31 | Skr2.24 | Skr13.50 | x |
| 2022-12-31 | Skr131.65 | Skr13.50 | x |
| 2023-12-31 | Skr56.66 | Skr13.50 | x |
| 2024-12-31 | Skr32.56 | Skr13.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Real Heart utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -51.01%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.24x
- Recent ROE (-51.01%) is below the historical average (-28.22%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2010 | -13.00% | -973258.33% | 0.00x | 1.08x | Skr-206.65K |
| 2011 | -10.66% | -8659500.00% | 0.00x | 1.08x | Skr-167.80K |
| 2012 | -1.69% | 0.00% | 0.00x | 1.55x | Skr-93.33K |
| 2013 | -47.69% | -58239.28% | 0.00x | 2.56x | Skr-312.10K |
| 2014 | -22.54% | -746.94% | 0.03x | 1.11x | Skr-2.44 Million |
| 2015 | -25.66% | -1034.08% | 0.02x | 1.11x | Skr-2.13 Million |
| 2016 | -23.97% | -2927.48% | 0.01x | 1.25x | Skr-5.50 Million |
| 2017 | -49.94% | -1773.49% | 0.02x | 1.23x | Skr-16.50 Million |
| 2018 | -45.89% | -7955.31% | 0.00x | 1.42x | Skr-10.79 Million |
| 2019 | -12.36% | 0.00% | 0.00x | 1.13x | Skr-13.19 Million |
| 2020 | -12.30% | 0.00% | 0.00x | 1.09x | Skr-15.99 Million |
| 2021 | -9.42% | 0.00% | 0.00x | 1.06x | Skr-21.61 Million |
| 2022 | -14.33% | -139880.00% | 0.00x | 1.23x | Skr-23.75 Million |
| 2023 | -82.86% | 0.00% | 0.00x | 1.25x | Skr-76.18 Million |
| 2024 | -51.01% | 0.00% | 0.00x | 1.24x | Skr-41.08 Million |
Industry Comparison
This section compares Real Heart's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $75,200,026
- Average return on equity (ROE) among peers: -74.39%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Real Heart (HEART) | Skr74.35 Million | -13.00% | 0.18x | $4.88 Million |
| Acarix A/S (ACARIX) | $76.60 Million | -60.65% | 0.08x | $28.86 Million |
| Arcoma AB (ARCOMA) | $12.52 Million | -92.85% | 4.66x | $8.93 Million |
| Bactiguard Holding AB (publ) (BACTI-B) | $353.18 Million | -39.18% | 0.87x | $19.20 Million |
| CellaVision AB (CEVI) | $20.07 Million | 13.08% | 1.20x | $262.59 Million |
| Clinical Laserthermia Systems AB (publ) (CLS-B) | $65.69 Million | -72.50% | 0.20x | $13.78 Million |
| Chordate Medical Holding AB (CMH) | $38.95 Million | -55.88% | 0.13x | $17.64K |
| Coala Life Group AB (COALA) | $52.33 Million | -287.99% | 0.53x | $468.93K |
| C-Rad AB (publ) (CRAD-B) | $93.64 Million | 22.63% | 0.57x | $56.67 Million |
| Duearity AB (DEAR) | $-2.39 Million | 0.00% | 0.00x | $34.43K |
| Episurf Medical AB (publ) (EPIS-B) | $41.40 Million | -170.53% | 0.39x | $5.40 Million |